Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $157000.0.

  • Niagen Bioscience's Depreciation & Amortization (CF) fell 426.83% to $157000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $624000.0, marking a year-over-year decrease of 943.4%. This contributed to the annual value of $663000.0 for FY2024, which is 2379.31% down from last year.
  • As of Q3 2025, Niagen Bioscience's Depreciation & Amortization (CF) stood at $157000.0, which was down 426.83% from $158000.0 recorded in Q2 2025.
  • Niagen Bioscience's Depreciation & Amortization (CF)'s 5-year high stood at $235000.0 during Q3 2022, with a 5-year trough of $151000.0 in Q4 2024.
  • For the 5-year period, Niagen Bioscience's Depreciation & Amortization (CF) averaged around $198157.9, with its median value being $211000.0 (2021).
  • In the last 5 years, Niagen Bioscience's Depreciation & Amortization (CF) surged by 1343.28% in 2023 and then plummeted by 2961.37% in 2024.
  • Niagen Bioscience's Depreciation & Amortization (CF) (Quarter) stood at $211000.0 in 2021, then rose by 4.74% to $221000.0 in 2022, then dropped by 19.91% to $177000.0 in 2023, then decreased by 14.69% to $151000.0 in 2024, then grew by 3.97% to $157000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $157000.0 in Q3 2025, compared to $158000.0 in Q2 2025 and $158000.0 in Q1 2025.